SECTOR:

Other therapeutics

FUND/VEHICLE:

Pivotal US

INVESTMENT DATE:

2022

GEOGRAPHY:

North America

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

Arkuda Therapeutics is a biotechnology company applying insights into lysosomal and microglial biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead program aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer’s Disease and Parkinson’s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pivotal bioVenture Partners, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, Surveyor Capital (a Citadel company), and Eli Lilly and Company.